Corbus Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on the stock and has a $40.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Andres Y. Maldonado has given his Buy rating due to a combination of factors tied to Corbus’s advancing pipeline and upcoming milestones. He highlights CRB-701’s strong efficacy and clean safety profile across several tumor types, with response rates that appear competitive versus existing Nectin-4 antibody-drug conjugates and fewer serious adverse events, which supports its potential best-in-class positioning.
He also points to the broad activity of CRB-701 across different HPV status and Nectin-4 expression levels, suggesting a larger addressable market in cancers with limited options, while upcoming FDA interactions and Phase 2/3 planning could unlock further value. In addition, he views early data from the obesity candidate CRB-913 as encouraging, noting meaningful short-term weight loss, favorable tolerability, and a design aimed at reducing neuropsychiatric risks, together creating a balanced portfolio with both near-term oncology catalysts and longer-term upside in obesity.
In another report released yesterday, William Blair also reiterated a Buy rating on the stock with a $8.90 price target.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CRBP in relation to earlier this year.